Gefitinib plus clocetaxel in non-small-cell lung cancer

被引：1
|
作者：
Costa, Daniel B. [1 ]
Kobayashi, Susumu [1 ]
机构：
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
来源：
LANCET | 2009年 / 373卷 / 9663期
关键词：
D O I：
10.1016/S0140-6736(09)60193-8
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：541 / 541
页数：1
相关论文
共 50 条
  • [21] Gefitinib in recurrent non-small-cell lung cancer: An IDEAL trial?
    Johnson, DH
    Arteaga, CL
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2227 - 2229
  • [22] Gefitinib for Chinese patients with advanced non-small-cell lung cancer
    Xiaotong, Z
    Longyun, L
    Xinlin, MU
    LUNG CANCER, 2004, 45 : S79 - S79
  • [23] EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
    Kobayashi, S
    Boggon, TJ
    Dayaram, T
    Janne, PA
    Kocher, O
    Meyerson, M
    Johnson, BE
    Eck, MJ
    Tenen, DG
    Halmos, B
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08): : 786 - 792
  • [24] Efficacy of chemotherapy plus gefitinib treatment in advanced non-small-cell lung cancer patients following acquired resistance to gefitinib
    Song, Zhengbo
    Zhang, Yiping
    MOLECULAR AND CLINICAL ONCOLOGY, 2013, 1 (05) : 875 - 878
  • [25] Nivolumab plus ipilimumab in non-small-cell lung cancer
    Reck, Martin
    Borghaei, Hossein
    O'Byrne, Kenneth J.
    FUTURE ONCOLOGY, 2019, 15 (19) : 2287 - 2302
  • [26] Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer
    Bersanelli, Melissa
    Tiseo, Marcello
    Banna, Giuseppe L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 874 - 875
  • [27] Erlotinib in advanced non-small-cell lung cancer after gefitinib failure
    Zheng-Tao Zhou
    Xin-Hua Xu
    Qing Wei
    Ming-qian Lu
    Jie Wang
    Cai-Hong Wen
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 1123 - 1127
  • [28] Docetaxel plus cisplatin in non-small-cell lung cancer
    Chandra Belani
    Sakkaraiappan Ramalingam
    Vassilis Georgoulias
    George Simon
    Drugs & Therapy Perspectives, 2004, 20 (3) : 7 - 9
  • [29] Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
    Tiseo, M.
    Bartolotti, M.
    Gelsomino, F.
    Bordi, P.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2010, 4 : 81 - 98
  • [30] Gefitinib maintenance in stage III non-small-cell lung cancer - Reply
    Kelly, Karen
    Redman, Mary W.
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) : 4850 - 4851
12345